JP2009530295A5 - - Google Patents

Info

Publication number

JP2009530295A5

JP2009530295A5 JP2009500483A JP2009500483A JP2009530295A5 JP 2009530295 A5 JP2009530295 A5 JP 2009530295A5 JP 2009500483 A JP2009500483 A JP 2009500483A JP 2009500483 A JP2009500483 A JP 2009500483A JP 2009530295 A5 JP2009530295 A5 JP 2009530295A5

Authority

JP

Japan

Prior art keywords

cocktail

administering

therapy

nucleoside analog

pharmaceutically acceptable

Prior art date

2007-03-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 26
• 239000002777 nucleoside Substances 0.000 claims 17
• 150000003833 nucleoside derivatives Chemical class 0.000 claims 13
• 238000002560 therapeutic procedure Methods 0.000 claims 12
• 239000000651 prodrug Substances 0.000 claims 11
• 229940002612 prodrug Drugs 0.000 claims 11
• 241000124008 Mammalia Species 0.000 claims 9
• 150000001875 compounds Chemical class 0.000 claims 8
• 239000003937 drug carrier Substances 0.000 claims 8
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 150000003839 salts Chemical class 0.000 claims 6
• 102100034343 Integrase Human genes 0.000 claims 5
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 5
• 230000001028 anti-proliverative effect Effects 0.000 claims 5
• 238000011282 treatment Methods 0.000 claims 5
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 4
• -1 acyclic nucleoside Chemical class 0.000 claims 4
• 230000006907 apoptotic process Effects 0.000 claims 4
• 210000004027 cell Anatomy 0.000 claims 4
• 230000003287 optical effect Effects 0.000 claims 4
• 108010017842 Telomerase Proteins 0.000 claims 3
• 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims 3
• 230000001093 anti-cancer Effects 0.000 claims 3
• 239000002246 antineoplastic agent Substances 0.000 claims 3
• 230000001939 inductive effect Effects 0.000 claims 3
• 239000003112 inhibitor Substances 0.000 claims 3
• 210000004881 tumor cell Anatomy 0.000 claims 3
• 239000004480 active ingredient Substances 0.000 claims 2
• 238000011319 anticancer therapy Methods 0.000 claims 2
• 229960002656 didanosine Drugs 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 230000006698 induction Effects 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
• ATKOZYBRBNGECU-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-methylpyrimidine-2,4-dione Chemical compound CC1=CN(COCCO)C(=O)NC1=O ATKOZYBRBNGECU-UHFFFAOYSA-N 0.000 claims 1
• PEIRNIBZTBBIHT-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=NC2=C1N=CN2COCCO PEIRNIBZTBBIHT-UHFFFAOYSA-N 0.000 claims 1
• FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical compound C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 claims 1
• 230000005778 DNA damage Effects 0.000 claims 1
• 231100000277 DNA damage Toxicity 0.000 claims 1
• 241001465754 Metazoa Species 0.000 claims 1
• 206010070834 Sensitisation Diseases 0.000 claims 1
• 230000002159 abnormal effect Effects 0.000 claims 1
• 230000032823 cell division Effects 0.000 claims 1
• 230000004663 cell proliferation Effects 0.000 claims 1
• 239000002552 dosage form Substances 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 210000004962 mammalian cell Anatomy 0.000 claims 1
• 229940127073 nucleoside analogue Drugs 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 claims 1
• 230000002062 proliferating effect Effects 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 230000008313 sensitization Effects 0.000 claims 1
• 230000001235 sensitizing effect Effects 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
• 108091035539 telomere Proteins 0.000 claims 1
• 102000055501 telomere Human genes 0.000 claims 1
• 210000003411 telomere Anatomy 0.000 claims 1
• 229940113082 thymine Drugs 0.000 claims 1